South Korea’s Samsung Bioepis started U.S sales of its copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.
Eli Lilly and Nektar Therapeutics announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.
U.S. Food and Drug Administration Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
Shares of Israel-based NeuroDerm Limited soared more than 16 percent in premarket trading after the company announced it was being snapped up by Tokyo-based Mitsubishi Tanabe Corporation.
A seven-year Republican effort to repeal and replace Obamacare faces a major test in the U.S. Senate, where lawmakers will decide whether to move forward and vote on a bill whose details and prospects are uncertain.
Discovery Worldwide, a healthcare communications agency that combines the power of science, storytelling and innovative delivery to move health forward, announced the appointment of Rico Ricketson as Head of Client Services.
A European Medicines Agency (EMA) panel recommended Roche’s immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval during 2017.
The EMA’s CHMP granted a positive opinion for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age.
FDA granted orphan-drug exclusivity for Haegarda for the prevention of hereditary angioedema attacks.
Corning announced at President Trump’s “Made in America” event that the company planned to create 1,000 new high-tech jobs in the U.S.